14.51
前日終値:
$14.42
開ける:
$14.43
24時間の取引高:
1.03M
Relative Volume:
0.73
時価総額:
$12.11B
収益:
$3.85B
当期純損益:
$667.93M
株価収益率:
22.09
EPS:
0.657
ネットキャッシュフロー:
$142.30M
1週間 パフォーマンス:
+2.04%
1か月 パフォーマンス:
+0.69%
6か月 パフォーマンス:
+8.69%
1年 パフォーマンス:
-12.18%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
RDY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RDY
Dr Reddys Laboratories Ltd Adr
|
14.51 | 11.84B | 3.85B | 667.93M | 142.30M | 0.657 |
![]()
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-05 | アップグレード | HSBC Securities | Hold → Buy |
2024-12-19 | ダウングレード | Nomura | Buy → Neutral |
2024-01-11 | ダウングレード | Jefferies | Buy → Underperform |
2023-08-29 | ダウングレード | HSBC Securities | Buy → Hold |
2023-05-18 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2023-03-17 | アップグレード | BofA Securities | Neutral → Buy |
2023-01-30 | 開始されました | JP Morgan | Underweight |
2022-11-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
2022-01-03 | 再開されました | BofA Securities | Neutral |
2021-07-27 | ダウングレード | Credit Suisse | Outperform → Neutral |
2021-02-02 | アップグレード | Barclays | Equal Weight → Overweight |
2020-09-18 | アップグレード | BofA Securities | Neutral → Buy |
2020-09-18 | アップグレード | Investec | Sell → Hold |
2020-01-28 | ダウングレード | CLSA | Buy → Outperform |
2020-01-27 | ダウングレード | CLSA | Buy → Outperform |
2020-01-09 | アップグレード | Citigroup | Sell → Buy |
2019-11-04 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-09-04 | アップグレード | Credit Suisse | Underperform → Outperform |
2019-07-01 | アップグレード | Macquarie | Neutral → Outperform |
2019-06-20 | 開始されました | Deutsche Bank | Hold |
2019-06-11 | 開始されました | Barclays | Equal Weight |
2019-05-20 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2019-02-19 | アップグレード | CLSA | Outperform → Buy |
2019-01-17 | ダウングレード | Citigroup | Neutral → Sell |
2017-09-21 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-08-31 | アップグレード | CLSA | Underperform → Outperform |
2017-07-28 | ダウングレード | CLSA | Underperform → Sell |
2016-07-27 | ダウングレード | HSBC Securities | Hold → Reduce |
2016-07-27 | ダウングレード | Jefferies | Hold → Underperform |
2016-02-10 | アップグレード | Credit Agricole | Underperform → Buy |
2015-11-10 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Dr Reddys Laboratories Ltd Adr (RDY) 最新ニュース
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
LLY Stock Quote Price and Forecast - CNN
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Validea's Top Health Care Stocks Based On Peter Lynch7/28/2025 - Nasdaq
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - MSN
Asian ADRs Retreat As Mixed Results Hit The Market - Finimize
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley initiates coverage on Dr. Reddy’s stock with Equalweight rating - Investing.com India
Dr Reddy's Laboratories among four key stocks to trade ex-dividend today - Mint
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
Trump Tariffs: Dr Reddys To Lupin — Pharma Stocks To Be In Focus After Threat Of 200% Levies - NDTV Profit
Five Pharma stocks see price target cuts, some downgraded by Macquarie - CNBC TV18
Mixed Movements In Asian Equities As Some Sectors Shine - Finimize
Full Truck Alliance Co. Ltd. Sponsored ADR (NYSE:YMM) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Dr Reddys Laboratories Ltd Adr (RDY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):